Brincidofovir

Summary

Brincidofovir (CHEMBL203321) is an approved small molecule (ATC J05AB17); indicated across 8 conditions including viral infectious disease and smallpox.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J05AB17
• Indications: 8 conditions
• Clinical trials: 22
• Chemistry: 561.7 Da · C27H52N3O7P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL203321
Name	Brincidofovir
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	483477
ATC	J05AB17
Molecular formula	C27H52N3O7P
Molecular weight	561.7
InChIKey	WXJFKKQWPMNTIM-VWLOTQADSA-N

SMILES: CCCCCCCCCCCCCCCCOCCCOP(=O)(CO[C@@H](CN1C=CC(=NC1=O)N)CO)O

IUPAC name: [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid

Also known as: Brincidofovir, CMX 001, CMX-001, CMX001, Hdp-cidofovir, Hexadecyloxypropyl cidofovir, Hexadecyloxypropyl-cidofovir, Tembexa, HDP-CDV, hexadecyloxypropyl cidofovir, BRINCIDOFOVIR

Patent coverage: 281 distinct patent families (685 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

8 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
viral infectious disease	4	MONDO:0005108	EFO:0000763
smallpox	4	MONDO:0004651	MONDO:0004651
cytomegalovirus infection	3	MONDO:0005132	EFO:0001062
adenoviridae infectious disease	3	MONDO:0043479	EFO:1001259
Ebola hemorrhagic fever	2	MONDO:0005737	EFO:0007243
pharyngoconjunctival fever	2	MONDO:0005911	EFO:0007434
liver disorder	1	MONDO:0005154	EFO:0001421

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 22.

Phase distribution

Phase	Trials
PHASE2	8
PHASE3	6
PHASE1	3
Not specified	3
PHASE1/PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07387367	PHASE3	RECRUITING	A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
NCT01143181	PHASE3	COMPLETED	Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses
NCT01769170	PHASE3	COMPLETED	A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients
NCT02087306	PHASE3	COMPLETED	Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection
NCT02439957	PHASE3	TERMINATED	A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus
NCT02439970	PHASE3	TERMINATED	A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease
NCT07511049	PHASE2	RECRUITING	Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study
NCT00793598	PHASE1/PHASE2	COMPLETED	CMX001 in Post-transplant Patients With BK Virus Viruria
NCT00942305	PHASE2	COMPLETED	Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients
NCT01241344	PHASE2	COMPLETED	Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease
NCT02271347	PHASE2	WITHDRAWN	An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease
NCT03339401	PHASE2	TERMINATED	The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation
NCT03532035	PHASE2	WITHDRAWN	Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia
NCT04268966	PHASE2	WITHDRAWN	An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola
NCT05511779	PHASE2	TERMINATED	Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation
NCT06761677	PHASE1/PHASE2	SUSPENDED	A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
NCT00780182	PHASE1	COMPLETED	Comparative Bioavailability and Effect of Food on CMX001 in Healthy Volunteers
NCT05391724	PHASE1	COMPLETED	Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects
NCT05935917	PHASE1	COMPLETED	Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults
NCT02167685	Not specified	TERMINATED	The Chimerix CMX001 Registry
NCT02420080	Not specified	TERMINATED	A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304
NCT02596997	Not specified	NO_LONGER_AVAILABLE	Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 1 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).